Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression

AIDS

Volumn 14, Issue 12, 2000, Pages 1709-1715

  Orenstein, Jan Marc ^a,e   Bhat, Niranjan ^b   Yoder, Christian ^c   Fox, Cecil ^d   Polis, Michael A ^b   Metcalf, Julia A ^b   Kovacs, Joseph A ^c   Falloon, Judith ^b   Walker, Robert E ^b   Masur, Henry ^c   Lane, H Clifford ^b   Davey, Richard T ^b  

^a GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Molecular Histology Labs   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AIDS; HAART; HIV; Immunohistochemistry; In situ hybridization; Lymph nodes

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HISTONE H3; KI 67 ANTIGEN; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE; LYMPHOCYTE COUNT; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODES; MICROSCOPY, ELECTRON; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 0033827460     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200008180-00004     Document Type: Article

References (39)

1. Antiretroviral treatment in 1998
2. T cell changes after combined nucleoside analogue therapy in HIV primary infection
3. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years
4. Decay characteristics of HIV-1-infected compartments during combination therapy
5. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
6. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
7. Viral dynamics in human immunodeficiency virus type 1 infection
8. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy
9. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/mL
10. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
11. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
12. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
13. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus
14. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
15. Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells
16. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
17. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
18. Control of HIV despite the discontinuation of antiretroviral therapy
19. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
20. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
21. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy
22. Rebound of plasma HIV viral load following prolonged suppression with combination therapy
23. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
24. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection
25. Lymph node architecture preceding and following 6 months of potent antiviral therapy: Follicular hyperplasia persists in parallel with p24 antigen. Restoration after involution and CD4 cell depletion in an AIDS patient
26. In situ hybridization for detection of HIV RNA in cells and tissues
27. Macrophages as a source of HIV during opportunistic infections
28. A rapid method to determine proliferation patterns of normal and malignant tissues by H3 histone mRNA in situ hybridization
29. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy
30. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
31. Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution
32. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue
33. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
34. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
35. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
36. HIV-1 replication in patients with undetectable plasma virus receiving HAART
37. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in Rhesus monkeys
38. Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells
39. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy